A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

NCT ID: NCT04998851

Last Updated: 2026-01-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-16
• Study Completion Date: 2025-01-13

Brief Summary

This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.

Conditions

Multiple Sclerosis; Clinically Isolated Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Women with CIS or MS

Lactating women with CIS or MS (in line with the locally approved indications) who decided together with their treating physician to continue on, or start treatment with, OCREVUS (ocrelizumab) post-partum. Women resuming treatment with ocrelizumab post-partum will be included only if the last exposure to ocrelizumab occurred more than 3 months before the last menstrual period to exclude any interference between fetal exposure and exposure via lactation.

Group Type: EXPERIMENTAL

Ocrelizumab

Intervention Type: DRUG

Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.

Interventions

Ocrelizumab

Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Woman is between 18 and 40 years of age at screening
• Woman is willing to breastfeed for at least 60 days after the first post-partum ocrelizumab infusion (this decision is to be taken prior to and independent from study participation)
• Woman is willing to provide breastmilk samples
• Woman has a diagnosis of MS or CIS (in line with the locally approved indications)
• Woman has delivered a healthy term singleton infant (≥37 weeks gestation)
• Infant is between 2-24 weeks of age at the time of the mother's first post-partum dose of ocrelizumab
• For women who received commercial ocrelizumab (OCREVUS) before enrolment: documentation that last exposure to ocrelizumab occurred more than 3 months before the last menstrual period (LMP) and was given at the approved dose of 2 x 300 mg or 1 x 600 mg
• Woman agrees to use acceptable contraceptive methods during the study

Exclusion Criteria

• Hypersensitivity to ocrelizumab or to any of its excipients
• Received last dose of ocrelizumab <3 months before the LMP or during pregnancy
• Active infections (may be included once the infection is treated and is resolved; women with bilateral mastitis infection should not have samples collected until the infection is completely resolved)
• Prior or current history of primary or secondary immunodeficiency, or woman in an otherwise severely immunocompromised state
• Known active malignancies, or being actively monitored for recurrence of malignancy
• History of breast implants, breast augmentation, breast reduction surgery or mastectomy
• Prior or current history of chronic alcohol abuse or drug abuse
• Positive screening tests for hepatitis B
• Treatment with a DMT for CIS or MS during pregnancy and/or first weeks post-partum, with the exception of formulations of interferon-beta, glatiramer acetate or pulsed corticosteroids
• Treatment with drugs known to transfer to the breastmilk and with established or potential deleterious effects for the infant
• Treatment with any investigational agent within 6 months or five half-lives of the investigational drug prior to the LMP

• >24 weeks of life at the time of the mother's first dose of ocrelizumab
• Any abnormality that may interfere with breastfeeding or milk absorption
• Active infection (may be included once the infection resolves)
• Infant has any other medical condition or abnormality that, in the opinion of the investigator, could compromise the infant's ability to participate in this study, including interference with the interpretation of study results
• At least one documented brief resolved unexplained event (BRUE), as defined by the 2016 Guidelines of the American Academy of Pediatrics

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

PPD Development, LP

INDUSTRY

Sponsor Role: collaborator

Laboratory Corporation of America

INDUSTRY

Sponsor Role: collaborator

Illingworth Research Group

UNKNOWN

Sponsor Role: collaborator

Hoffmann-La Roche

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

University of California San Francisco

San Francisco, California, United States

University Of Colorado

Aurora, Colorado, United States

Northwestern Memorial Hospital

Chicago, Illinois, United States

Brigham and Womens Hospital

Boston, Massachusetts, United States

Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis

Owosso, Michigan, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Hosp. Clinico San Carlos

Madrid, , Spain

Queen Mary University of London

London, , United Kingdom

Countries

United States; Spain; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2021-000063-79

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MN42989

Identifier Type: -

Identifier Source: org_study_id